Estimated Reading Time: 9 min Introduction
With a distinguished career spanning scientific research, global biopharma leadership, and board governance, Alexandre Lebeaut
, brings a rare combination of scientific depth, executive leadership, and strategic insight. In this exclusive interview, he shares his perspective on Excelya, the transformation of the CRO industry, and the foundations of high-impact partnerships in today’s increasingly complex R&D landscape.
The Interview
Meet Board Member Alexandre Lebeaut
-
Your background bridges biopharma leadership, scientific advisory roles, and board governance. Which experiences have most shaped your approach to decision-making in the life sciences sector?
Alexandre shares: “First and foremost, working as a pediatrician gave me a ‘patient-first’ passion and compass that guides every decision I make. I have been privileged to contribute to developing pipelines and R&D organizations of all sizes on a global basis. Two key words define my approach: scientific integrity and adaptability. You must always listen to the data and maintain an open, curious mind. I am a strong advocate for question-based, TPP-driven development strategies. Successful decision-making requires balancing the operational discipline of a large organization while preserving the entrepreneurial audacity required to develop breakthrough therapies. Ultimately, it is always about delivering value for patients, healthcare providers, the company, and investors.”
-
What first attracted you to Excelya and convinced you to join its Board of Directors?
Alexandre shares: “I was drawn to Excelya’s unique energy, resilience, and ambition, primarily embodied by its two founders. Excelya’s ‘people-first’ culture isn’t just a tagline; it’s a tangible operational reality. Unlike many CROs that have become transactional giants, Excelya retains a partner-centric DNA. I saw an opportunity to help guide a European champion ready to scale globally without losing its soul. The ambition to be the leader and preferred partner for large and mid-sized pharma and biotech companies, offering a level of dedication and scientific engagement that larger organizations often struggle to provide, was the deciding factor.”
“Big enough to deliver, small enough to care, one sponsor at a time.”
What Makes Excelya Unique
-
From your perspective, what makes Excelya unique among CROs today, scientifically, operationally, or culturally?
Alexandre shares: “The ‘One Team’ approach, combined with a strong culture and values that respect, develop, and retain talent, is a real differentiator. Partnering with sponsors has true meaning, being an efficient extension of the sponsor’s team. Scientifically, Excelya distinguishes itself by moving beyond simple execution into strategic scientific advisory, particularly in complex therapeutic areas like oncology. Operationally, Excelya’s flexibility, offering full-service models, FSP, and resourcing, allows the company to meet all sponsor needs as a ‘One Stop Shop.’ This combination of scientific rigor and operational care creates a unique value proposition. I would say: ‘Big enough to deliver, small enough to care,’ one sponsor at a time.”
Evolving Sponsors Expectations
-
How do you see the expectations of pharma and biotech sponsors evolving, and how is Excelya adapting to meet those needs?
Alexandre shares: “Today, sponsors are no longer looking for mere service providers; they need strategic partners who can improve development strategies and tactics. There is growing demand for ‘intelligent execution’, using data to predict roadblocks before they happen. Excelya is adapting by integrating advanced technologies and efficient processes to maintain regulatory compliance and integrity, while retaining a well-trained and dynamic professional workforce across all countries. For sponsors, quality is a given, but time and cost must be managed effectively through proactive problem-solving and transparent communication.”
-
The CRO industry is experiencing rapid transformation. What major shifts do you anticipate in the next 5 to 10 years?
Alexandre shares: “Timely execution of clinical trials has always been at the center of sponsors’ questions and concerns. A key question is: how can we further de-risk their investments?”
“We will see a definitive shift toward integrating AI and ‘digital twins’ to optimize trial design and patient stratification, with an increased role for biomarkers, at the onset of clinical programs. The traditional linear model of clinical development will evolve into a more adaptive, data-driven ecosystem. Additionally, decentralized clinical trials will grow, requiring CROs to master logistics and remote data capture. The winners will be those who can harness these technologies to reduce cost and time without compromising quality and regulatory compliance.”
-
In your opinion, what are the most critical success factors for CRO sponsor partnerships, especially for emerging biotech companies?
Alexandre shares: “The most critical success factors are: 1) alignment of objectives and incentives, and 2) efficient, transparent communication that delivers timely, actionable feedback (‘How are we doing?’ and ‘How can we improve?’). For emerging biotechs, speed and capital efficiency are paramount. A successful partnership requires close alignment on shared objectives and deliverables, so the CRO helps the biotech reach value inflection points to attract funding. A key word here is trust. When a CRO acts with care and ownership, treating the asset as if it were their own, we create the trust and environment necessary for mutual success.”
“At Excelya, I am motivated by the energy of its leaders and teams, their curiosity, ambition, and drive for higher performance. Mentoring the next generation of industry leaders, while helping Excelya grow into a global force that brings innovation to patients better and faster, is incredibly rewarding.”
CRO’s Success Factors
-
In your opinion, what are the most critical success factors for CRO–sponsor partnerships, especially for emerging biotech companies?
Alexandre shares: “The most critical success factors are: Alignment of objectives and incentives, and Efficient, transparent communication that delivers timely, actionable feedback (‘How are we doing?’ and ‘How can we improve?’). For emerging biotechs, speed and capital efficiency are paramount. A successful partnership requires close alignment on shared objectives and deliverables, so the CRO helps the biotech reach value inflection points to attract funding. A key word here is trust. When a CRO acts with care and ownership, treating the asset as if it were their own, we create the trust and environment necessary for mutual success.”
-
From a strategic and scientific standpoint, how do you see Excelya best positioned to support the increasingly complex needs of today’s clinical development landscape, whether in advanced therapies, precision medicine, or new trial models?
Alexandre shares: “Excelya is very well-sized to navigate the complexity of both present and future clinical research. Excelya’s footprint and model is also a key differentiator versus competitors: providing optimal geographical coverage in the EU while maintaining centralized, agile governance.”
Excelya’s expertise in advanced therapies enables us to support precision medicine trials that require specialized site networks and biomarker logistics. Being a learning organization, leveraging lessons learned, best practices, and scientific and regulatory training through advisory boards, combined with introducing AI-based technologies to augment performance, are two key differentiators for Excelya.”
A Leading European CRO: Excelya
-
If you had to define Excelya’s biggest opportunity for impact in the coming years, what would it be?
Alexandre shares: “Excelya’s biggest opportunity is to become the leading European CRO that also bridges the gap to the US biopharma market. With fragmentation in the CRO market, there is a clear path for a company that offers premium, scientifically led services at a global scale. By leveraging its partnership with Eurazeo to fuel external growth and technology investment, Excelya can set a new industry standard by offering an unparalleled range of services, from full-service to FSP and resourcing, that deliver value for sponsors.”
-
What advice would you give to biotech founders and R&D leaders looking to accelerate development while maintaining scientific integrity?
Alexandre shares: “Do not conflate speed with rushing. Invest heavily in protocol design and feasibility assessments upfront. The most expensive delays happen because of poor planning, not slow execution. My advice is to identify a CRO partner early who can challenge your assumptions about enrollment, note that investigative sites often overestimate their capabilities, and bring actionable operational, regulatory, and scientific experience to the table. Ask yourself honestly: ‘What keeps me awake at night?’ Trust in your CRO partner to deliver on agreed criteria, data quality, time, and cost, is essential. But as the saying goes, ‘it takes two to tango,’ and you will need to nurture your partnership, closely monitoring and adapting your strategy to succeed.”
-
On a personal level, what motivates you most in your work with Excelya and the broader life sciences community?
Alexandre shares: “Ultimately, it goes back to my roots as a physician: the patient. Every protocol, every spreadsheet represents a life waiting for a solution. And patients can’t wait. At Excelya, I am motivated by the energy of its leaders and teams, their curiosity and ambition for higher performance. Mentoring the next generation of leaders in this industry and helping Excelya grow into a global force that brings innovation to patients better and faster is incredibly rewarding.”
Similar resources
